Ergot alkaloids in acute migraine therapy produce what effect and what are key contraindications?

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Ergot alkaloids abort acute migraine through powerful vasoconstriction of cranial blood vessels. This effect comes from activity at vascular smooth muscle receptors, notably partial agonist/agonist actions at 5-HT1B/1D receptors and alpha-adrenergic receptors. The result is reduced dilation and pulsation of cerebral vessels, which can relieve migraine symptoms. However, this vasoconstrictive action carries significant safety concerns, so their use is limited by important contraindications. They are not appropriate in pregnancy because constricting uterine vessels can harm the fetus or disrupt pregnancy. In uncontrolled hypertension, the added vasoconstriction can dangerously raise blood pressure and risk ischemia. Hepatic or renal impairment reduces clearance and increases exposure, heightening toxicity. Recent use of triptans or other serotonergic/vasoconstrictive medications is a concern because combining vasoconstrictors raises the risk of severe vasospasm and ischemia. For these reasons, ergot alkaloids are not first-line for all patients and are reserved for specific scenarios with careful consideration of risks.